Osilodrostat phosphate is a Small Molecule owned by Recordati, and is involved in 19 clinical trials, of which 17 were completed, 1 is ongoing, and 1 is planned.

Osilodrostat (LCI-699) is an aldosterone synthase inhibitor (ASI). Aldosterone is the principal mineralocorticoid in humans and a critical regulator of fluid and electrolyte homeostasis. It regulates blood pressure via sodium and potassium and excessive aldosterone levels are associated with cardiovascular and renal damage via tissue remodeling.

The revenue for Osilodrostat phosphate is expected to reach a total of $3.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Osilodrostat phosphate NPV Report.

Osilodrostat phosphate was originated by Novartis and is currently owned by Recordati.

Osilodrostat phosphate Overview

Osilodrostat Phosphate (Isturisa) belongs to benzonitriles, acts as an corticosteroid. It is formulated as film coated tablets for oral route of administration. Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults, and for patients with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.

Osilodrostat (LCI-699) is under development for the treatment of pituitary ACTH hypersecretion (Cushing Disease), Cushing's syndrome. It is administered orally and acts by targeting aldosterone synthase. It was also under development for the treatment of primary hyperaldosteronism, heart failure, hypertension including essential hypertension, congestive heart failure and resistant hypertension.

Recordati Overview

Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.

The company reported revenues of (Euro) EUR1,580.1 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. In FY2021, the company’s operating margin was 31%, compared to an operating margin of 32.4% in FY2020. In FY2021, the company recorded a net margin of 24.4%, compared to a net margin of 24.5% in FY2020. The company reported revenues of EUR485.1 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Osilodrostat phosphate

Report Segments
  • Innovator (NME)
Drug Name
  • Osilodrostat phosphate
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Hormonal Disorders
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.